Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA* of Darmstadt, Germany, today announced that Vincent Donovan has been appointed Head of BioPharmaceutical Process Solutions at EMD Millipore. He will assume leadership effective July 1, 2012 and be based at the company’s Bedford, Massachusetts office.

Donovan joined Millipore Corporation in 1988 and has held numerous sales leadership roles including Senior Director, North American Field Operations, Bioprocess Division, and Director of Sales, BioPharmceutical Division.

“Vin brings a global perspective and broad experience in supporting life science customers from product development through manufacturing,” noted Andrew Bulpin, Executive Vice President of Process Solutions, EMD Millipore. “I look forward to working closely with Vin to expand and reinforce EMD Millipore’s leadership in the biopharmaceutical field. I am confident that his deep expertise will reinforce our position as the premier partner to bring customers’ molecules to market.”

Donovan holds a BA from Merrimack College in Massachusetts and an MBA from Rivier College in New Hampshire.

About EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2011 revenues of EUR 2.4 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of € 10.3 billion in 2011, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.